In what qualifies as a major breakthrough, meant to help the world battered by the novel coronavirus, a Russian University has claimed to have successfully completed trials of the first COVID-19 vaccine. All the volunteers who took part in the vaccine program are likely to be discharged by July 20.
Of the 21 vaccine candidates listed by the World Health Organization in clinical trial stages, two have reached phase III - the private Chinese company Sinovac's trial of an inactivated vaccine in Brazil, and the British-Swedish drug company AstraZeneca and the University of Oxford's viral vector vaccine that is in a Phase II/III trial in England and in Phase III trials in Brazil and South Africa.
He also stressed that any vaccine candidate must be introduced very cautiously, and that at least two years of clinical trials are usually required before it is massively applied to the population.
Professor Robin Shattock, who leads a team working to produce a vaccine at Imperial College London, said that enough of the vaccine would be available for every person in the United Kingdom if trials go "really well".
The vaccine has been produced by the Gamalei Institute of Epidemiology and Microbiology, Russia.
There is no certainty that the vaccine being developed with work though as its effectiveness depends on the level of immunity needed to prevent infection, which makes chances of success hard to predict.
"The research has been completed and it proved that the vaccine is safe". Even for ebola, the most recent vaccine approved for use by the World Health Organization, phase I trials began in November 2014, and the drug got World Health Organization approval for use in November 2019, a full five years later. As the third phase of human trials requires over 10,000 participants for the results to be valid, Thailand - due to its relatively low number of cases - will seek the cooperation of Brazil, India and Indonesia to carry out the tests.
"On Monday, 13 July, the second group of volunteers, who are tested for the efficiency and immunogenicity of the vaccine, will be injected with the second component of the vaccine against the coronavirus", the ministry stated.
The main objective of the first stage of the study "was to show the vaccine's safety on humans, which was successfully done", said Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University to Sputnik. The failure rate for vaccines in development is very high.
Russian Federation is now working on eight vaccines, according to Sputnik but according to the clinical trials website, 10 vaccine candidates have been listed.